| Citation: |
XU Manling, ZHU Jingbo, YU Kaiwen, CHEN Ling, FAN Huaying, FAN Qingtao, WANG Qiuping, LU Yan. Correlations of serum Apelin-13 and fatty acid binding protein 4 levels with postmenopausal osteoporosis[J]. Journal of Clinical Medicine in Practice, 2024, 28(11): 73-78, 83. DOI: 10.7619/jcmp.20240004
|
To investigate the correlations of serum Apelin-13 and fatty acid binding protein 4 (FABP4) levels with metabolic and bone metabolic indicators in postmenopausal women with different bone mass.
A total of 145 postmenopausal women were selected as subjects and divided into three groups based on bone mineral density (BMD) test results: normal bone mass group(49 cases), osteopenia (ON) group(51 cases), and osteoporosis (OP) group(45 cases). Serum Apelin-13, FABP4 levels, bone metabolic indicators, and biochemical indicators were measured and compared among the three groups. Spearman correlation analysis was used to analyze the correlations of Apelin-13, FABP4, and other indicators with BMD. Multivariate Logistic regression analysis was performed to analyze the risk factors for OP, and the receiver operating characteristic (ROC) curve was plotted to analyze the predictive value of serum Apelin-13 for postmenopausal osteoporosis (PMOP).
The serum Apelin-13 level in the OP group was lower than that in the ON group and the normal bone mass group (P < 0.05). No significant difference in serum FABP4 levels was found among the three groups (P>0.05). The levels of serum parathyroid hormone (PTH), alkaline phosphatase (ALP), type Ⅰ procollagen amino-terminal propeptide (PⅠNP), type Ⅰ collagen cross-linked C-terminal peptide (CTXⅠ), and bone-specific alkaline phosphatase (BALP) in the OP group were higher than those in the ON group and the normal bone mass group (P < 0.05). Lumbar post-menopause BMD was positively correlated with serum Apelin-13 levels (P < 0.05), but had no correlation with serum FABP4 levels (P>0.05). Lumbar BMD was negatively correlated with serum PTH, ALP, PⅠNP, CTXⅠ, BALP, and age (P < 0.05), but positively correlated with body weight, body mass index, T-score, fasting insulin, and insulin resistance index (P < 0.05). Multivariate Logistic regression analysis showed that serum Apelin-13, PTH, ALP, PⅠNP, CTXⅠ, and BALP levels were independent factors influencing the occurrence of OP in postmenopausal women (P < 0.05). ROC curve results showed that the optimal cut-off value of serum Apelin-13 for predicting PMOP was 18.51 pg/mL, with an area under the curve of 0.716, a sensitivity of 70.0%, and a specificity of 64.4%.
Apelin-13 is lowly expressed in the serum of PMOP patients, and its expression level is closely related to lumbar BMD, which may serve as an early screening indicator and potential therapeutic target for PMOP.
| [1] |
WANG L T, CHENdrug-induced osteoporosis: a cellular and molecular overview[J]. Int J Mol Sci, 2023, 24(6): 5814. doi: 10.3390/ijms24065814
|
| [2] |
中华医学会骨质疏松和骨矿盐疾病分会. 中国骨质疏松症流行病学调查及"健康骨骼" 专项行动结果发布[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(4): 317-318. doi: 10.3969/j.issn.1674-2591.2019.04.001
|
| [3] |
HU K, DEYA EDELEN E, ZHUO W Q, et al. Understanding the consequences of fatty bone and fatty muscle: how the osteosarcopenic adiposity phenotype uncovers the deterioration of body composition[J]. Metabolites, 2023, 13(10): 1056. doi: 10.3390/metabo13101056
|
| [4] |
GONG G, WAN W H, LIU X H, et al. Apelin-13, a regulator of autophagy, apoptosis and inflammation in multifaceted bone protection[J]. Int Immunopharmacol, 2023, 117: 109991. doi: 10.1016/j.intimp.2023.109991
|
| [5] |
FURUHASHI M, SAITOH S, SHIMAMOTO K, et al. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases[J]. Clin Med Insights Cardiol, 2015, 8(Suppl 3): 23-33.
|
| [6] |
XU A M, TSO A W K, CHEUNG B M Y, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study[J]. Circulation, 2007, 115(12): 1537-1543. doi: 10.1161/CIRCULATIONAHA.106.647503
|
| [7] |
SAUER T, FACCHINETTI G, KOHL M, et al. Protein expression of AEBP1, MCM4, and FABP4 differentiate osteogenic, adipogenic, and mesenchymal stromal stem cells[J]. Int J Mol Sci, 2022, 23(5): 2568. doi: 10.3390/ijms23052568
|
| [8] |
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15(6): 573-611. doi: 10.3969/j.issn.1674-2591.2022.06.001
|
| [9] |
FU X R, LIU G, HALIM A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8): 784. doi: 10.3390/cells8080784
|
| [10] |
LI J, CHEN X, LU L Y, et al. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis[J]. Cytokine Growth Factor Rev, 2020, 52: 88-98. doi: 10.1016/j.cytogfr.2020.02.003
|
| [11] |
KNOKE J D. Weight loss: a determinant of hip bone loss in older men and women: the rancho bernardo study[J]. Am J Epidemiol, 2003, 158(12): 1132-1138. doi: 10.1093/aje/kwg265
|
| [12] |
WEI Z H, GE F, CHE Y T, et al. Metabolomics coupled with pathway analysis provides insights into sarco-osteoporosis metabolic alterations and estrogen therapeutic effects in mice[J]. Biomolecules, 2021, 12(1): 41. doi: 10.3390/biom12010041
|
| [13] |
MILLER P D, HATTERSLEY G, RⅡS B J, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis[J]. JAMA, 2016, 316(7): 722. doi: 10.1001/jama.2016.11136
|
| [14] |
CUI Y Z, LV B, LI Z Y, et al. Bone-targeted biomimetic nanogels re-establish osteoblast/osteoclast balance to treat postmenopausal osteoporosis[J]. Small, 2024, 20(6): e2303494. doi: 10.1002/smll.202303494
|
| [15] |
BROWN J P, DON-WAUCHOPE A, DOUVILLE P, et al. Current use of bone turnover markers in the management of osteoporosis[J]. Clin Biochem, 2022, 109/110: 1-10. doi: 10.1016/j.clinbiochem.2022.09.002
|
| [16] |
GARNERO P, DELMAS P D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease[J]. J Clin Endocrinol Metab, 1993, 77(4): 1046-1053.
|
| [17] |
MIGLIORINI F, MAFFULLI N, SPIEZIA F, et al. Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review[J]. J Orthop Surg Res, 2021, 16(1): 351. doi: 10.1186/s13018-021-02497-0
|
| [18] |
姚颖, 刘玮. 骨代谢生化指标与绝经后骨质疏松性腰椎骨折的关系[J]. 实用临床医药杂志, 2020, 24(7): 112-115. doi: 10.7619/jcmp.202007032
|
| [19] |
CHEN L, SHI X, XIE J, et al. Apelin-13 induces mitophagy in bone marrow mesenchymal stem cells to suppress intracellular oxidative stress and ameliorate osteoporosis by activation of AMPK signaling pathway[J]. Free Radic Biol Med, 2021, 163: 356-368. doi: 10.1016/j.freeradbiomed.2020.12.235
|
| [20] |
LIU S P, WANG W L, YIN L L, et al. Influence of Apelin-13 on osteoporosis in Type-2 diabetes mellitus: a clinical study[J]. Pak J Med Sci, 2018, 34(1): 159-163.
|
| [21] |
TANG S Y, XIE H, YUAN L Q, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways[J]. Peptides, 2007, 28(3): 708-718. doi: 10.1016/j.peptides.2006.10.005
|
| [22] |
HAN X F, ZHANG X X, LIU K M, et al. Apelin-13 deficiency alters cortical bone geometry, organic bone matrix, and inhibits Wnt/β-catenin signaling[J]. Gen Comp Endocrinol, 2018, 267: 29-35. doi: 10.1016/j.ygcen.2018.05.024
|
| [23] |
KRALISCH S, FASSHAUER M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?[J]. Diabetologia, 2013, 56(1): 10-21. doi: 10.1007/s00125-012-2737-4
|
| [24] |
SONG C, TAN P, ZHANG Z, et al. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation[J]. FASEB J, 2018, 32(6): 3215-3228. doi: 10.1096/fj.201600825RRR
|
| [25] |
吴其胜, 马黎敏, 赵旭阳, 等. 2型糖尿病合并骨质疏松患者血清中FABP4、CMKLR1表达及临床意义[J]. 中国卫生检验杂志, 2023, 33(15): 1855-1859. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ202315016.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: